JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2015, Vol. 53 ›› Issue (2): 65-70.doi: 10.6040/j.issn.1671-7554.0.2014.119

Previous Articles     Next Articles

Expression of EZH2 protein and its role in ovarian epithelial tumor

CHEN Jing1, LI Chunyan1, ZHAO Miaoqing2, CUI Jingjing1, ZHANG Na3, FU Yibing1   

  1. 1. Department of Gynecology and Obstetrics, Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong, China;
    2. Department of Pathology, Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong, China;
    3. Department of Operation Anaesthesia, Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong, China
  • Received:2014-03-08 Published:2015-02-10

PDF (PC)

197

Abstract: Objective To explore the expression of EZH2 protein in different epithelial ovarian tumors and its possible role in tumor development. Methods Immunohistochemistry was used to detect EZH2 protein expression in 15 normal ovarian tissues, 32 ovarian benign tumors, 28 ovarian borderline tumors and 50 primary epithelial ovarian cancers. Real-time quantitative PCR (RT-PCR) was used to detect EZH2 mRNA expression in 15 normal ovarian tissues, 23 ovarian benign tumors, 23 borderline tumors and 25 epithelial ovarian cancers. Results ① EZH2 expressed highly in nucleus in epithelial ovarian cancers compared with normal ovarian tissue (P<0.01), benign tumor (P<0.01) and borderline tumor (P<0.05). EZH2 expression was significantly correlated with grade and staging of tumor in epithelial ovarian cancers (P<0.01, P<0.05). ② EZH2 protein expressed in cytoplasm in ovarian tumor, and it expressed highly in benign ovarian tumor and borderline tumor compared with epithelial ovarian cancers (P<0.05). ③ The nuclear expression of EZH2 protein in epithelial ovarian cancers was positively correlated with Ki-67 (r=0.40, P<0.01). Conclusion EZH2 protein expresses in both nucleus and cytoplasm in ovarian tumors, and its elevated nuclear expression in epithelial ovarian cancers is associated with not only staging and grade of tumor, but also cell proliferation.

Key words: Ovarian cancer, Ki-67, EZH2 protein, EZH2 mRNA, Cytoplasm

CLC Number: 

  • R737.31
[1] Jemal A, Siegel R, Xu JQ, et al. Cancer statistics[J]. Cancer J Clin, 2010, 60(5): 277-300.
[2] 毛晓韵, 姚凡, 金锋. EZH2与乳腺癌发生发展的关系[J]. 中华肿瘤防治杂志, 2010, 17(2): 149-152. MAO Xiaoyun, YAO Fan, JIN Feng. Relationship between EZH2 gene and carcinogenesis and progress of breast cancer[J]. Chin J Cancer Prev Treat, 2010, 17(2): 149-152.
[3] Min J, Zaslavsky A, Fedele G, et al. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κB[J]. Nat Med, 2010, 16(3): 286-294.
[4] Moore HM, Gonzalez ME, Toy KA, et al. EZH2 inhibition decreases p38 signaling and suppresses breast cancer motility and metastasis[J]. Breast Cancer Research and Treatment, 2013, 138(3): 741-752.
[5] Chang CJ, Hung MC. The role of EZH2 in tumor progression[J]. Br J Cancer, 2012, 106(2): 243-247.
[6] 褚金曼, 杜咏梅, 骆树瑜, 等. EZH2和Ki-67蛋白在腺样囊性癌中的表达及其临床意义[J]. 中国肿瘤临床, 2014, 41(5): 311-314. CHU Jinman, DU Yongmei, LUO Shuyu, et al. Expression of EZH2 and Ki-67 in salivary adenoid cystic carcinoma and their clinical significance[J]. Chinese Journal of Clinical Oncology, 2014, 41(5): 311-314.
[7] Ren G, Baritaki S, Marathe H, et al. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer[J]. Cancer Research, 2012, 72(12): 3091-3104.
[8] Au SL, Wong CC, Lee JM, et al. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis[J]. Hepatology, 2012, 56(2): 622-631.
[9] Crea F, Fornaro L, Bocci G, et al. EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis[J]. Cancer Metastasis Reviews, 2012, 31(3-4): 753-761.
[10] Xu L, Beckebaum S, Iacob S, et al. MicroRNA-101 inhibits human hepatocellular Carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity[J]. Journal of Hepatology, 2014, 60(3): 590-598.
[11] Fluge , Gravdal K, Carlsen E, et al. Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis[J]. Br J Cancer, 2009, 101(8): 1282-1289.
[12] Yon R. Linking JNK-STAT3-Akt signaling axis to EZH2 phosphorylation: A novel pathway of carcinogenesis[J]. Cell Cycle, 2013, 12(2): 202-203.
[13] Seward S, Semaan A, Qazi AM, et al. EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21(waf1/cip1) and by inhibiting mutant p53[J]. Cancer Letters, 2013, 336(1): 53-60.
[14] Jaenisch R, Young R. Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming[J]. Cell, 2008, 132(4): 567-582.
[15] Su IH, Dobenecker MW, Dickinson E, et al. Polycomb group protein ezh2 controls actin polymerization and cell signaling[J]. Cell, 2005, 121(3): 425-436.
[16] Sauteur L, Krudewig A, Herwig L, et al. Cdh5/VE-cadherin Promotes Endothelial Cell Interface Elongation via Cortical Actin Polymerization during Angiogenic Sprouting[J]. Cell Rep, 2014, 9(2): 504-13.
[1] ZHANG Xiying, ZHAI Chunyan, LI Jingsong, HAN Bo. Expression of EZH2 in Chinese Ewing sarcoma patients and its relationship with clinicopathological parameters and prognosis [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(2): 84-91.
[2] LU Heng, LIU Yanguo, LI Shuguang, CHEN Xiaokang, TIAN Qi, YI Cuihua, WANG Xiuwen. Regulation of epithelial ovarian carcinoma SKOV-3 cell migration by YKL-40 [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(1): 33-38.
[3] ZHAO Lu, JIAO Jun, ZHANG Teng, JIAO Xinlin, CUI Baoxia. Expression of LXRα in ovarian carcinoma and effects of T0901317 on SKOV3 cell line [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(1): 49-53.
[4] XIAO Junchao, JIANG Wen, NAN Hui, WANG Peirong. A recombinant adenovirus fiber knob protein sensitizes ovarian cancer cells to cetuximab therapy [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(5): 1-5.
[5] ZHAO Yunxia, SONG Jing, ZHANG Cancan, LIN Xueyan, WEI Wei, TIAN Yongjie. CXXC4 promotes sensitivity to chemotherapy drugs in epithelial ovarian cancer cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(3): 24-29.
[6] XU Zhihong, WU Xiaohua, YAO Tiezhu, WANG Xiaoxiang, DUAN Xiaoyang, SHI Jian. Relationship between mir-99a expression and prognosis of epithelial ovarian cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(3): 77-80.
[7] CUI Yong, ZHANG Rongxiang, WANG Fuli, WANG Guoying, FENG Jianlin, ZHANG Haixia. Clinical efficacy of BSD2000 deep hyperthermia combined with chemotherapy of TP regimen for advanced ovarian cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(7): 53-57.
[8] SONG Xinggui, CHEN Zijiang, MA Shuiying, WU Keliang, LI Mei. Effect of Gonadotrophin on the in vitro maturation of immature oocytes from controlled ovarian stimulation [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(7): 61-64.
[9] QIU Huihui1， YE Liping1， WEN Youfeng2， LI Dan1， SONG Jia1. Effects of IL-6 on the expressions of bcl-2，cyclinD1 and VEGF in ovarian cancer cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(6): 17-21.
[10] LI Yan, WEI Wei, LV Shuqing, TIAN Yongjie. Effects of PARP-1 on angiogenesis of ovarian cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(4): 97-101.
[11] ZHANG Miaoci, LI Ping, HA Minwin. Clinical observation of recombinant human endostatin combined with gemcitabine in the treatment of platinum-resistant recurrent ovarian cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(11): 55-59.
[12] XIE Fang, LIU Shuai, LIU Zheng, NIU Zhi-hong. NOV modulates expression of Ki-67,VEGF，p27 and COX-2 in renal clear cell carcinoma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(10): 29-32.
[13] ZHANG Yan-xia1， ZHANG Pei-jun2， YAN Yan-yan3， DUAN Ai-xu4， LI Jia-shan2, NIU San-qiang5. Expressions of Ki-67, PCNA and Survivin in gastrointestinal stromal tumor tissues [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(1): 67-70.
[14] ZHANG Qing-lu, HOU Gui-hua, LIANG Ting, SONG Jing, ZHANG Chao. Effect and clinical significance of ISO-1 in the invasion
of ovarian cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(9): 33-.
[15] QIAO Zhen1, LIU Pei-shu2, HAN Bing1, WANG Yu1. Smac mimic potentiates cisplatin-induced cell apoptosis of
ovarian cancer cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(6): 61-.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd